Resistance and Overcoming Resistance in Breast Cancer

References

• International Agency for Research on Cancer. Global cancer observatory. Cancer Today; 2018 Available from:https://gco.iarc.fr/. Accessed 113, 2020.
   Google Scholar
• WaksA, WinerE. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.1932330667505
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Global cancer observatory. Latest world cancer statistics – GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence Worldwide in 2012; 2013 Available from:https://www.iarc.fr/news-events/latest-world-cancer-statistics-globocan-2012-estimated-cancer-incidence-mortality-and-prevalence-worldwide-in-2012/. Accessed 113, 2020.
   Google Scholar
• BrayF, FerlayJ, LaversanneM, et al. Cancer I ncidence in F ive C ontinents: inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060–2071. doi:10.1002/ijc.2967026135522
   PubMed Web of Science ®Google Scholar
• HarbeckN, CortesJ, GnantM, et al. Breast cancer. Nat Rev. 2019;5(66). doi:10.1038/s41572-019-0111-2
   Google Scholar
• PratA, ParkerJS, KarginovaO, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. doi:10.1186/bcr263520813035
   PubMed Web of Science ®Google Scholar
• ParisotJP, HuXF, DeLuiseM, ZalcbergJR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer. 1999;79(5–6):693–700. doi:10.1038/sj.bjc.669011210070856
   PubMed Web of Science ®Google Scholar
• BerryD, MussH, ThorA, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor–positive, node-positive breast cancer. J Clin Oncol. 2000;18(20):3471–3479. doi:10.1200/JCO.2000.18.20.347111032587
   PubMed Web of Science ®Google Scholar
• TaiW, MahatoR, ChengK. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264–275. doi:10.1016/j.jconrel.2010.04.00920385184
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0.15894097
   PubMed Web of Science ®Google Scholar
• SpringLM, GuptaA, ReynoldsKL, et al. Neoadjuvant endocrine therapy for estrogen receptor–positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486. doi:10.1001/jamaoncol.2016.189727367583
   PubMed Web of Science ®Google Scholar
• RossiV, BerchiallaP, GiannarelliD, et al. Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers (Basel). 2019;11(11):1661. doi:10.3390/cancers11111661
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8.21802721
   PubMed Web of Science ®Google Scholar
• DroogM, BeelenK, LinnS, ZwartW. Tamoxifen resistance: from bench to bedside. Eur J Pharmacol. 2013;717(1–3):47–57. doi:10.1016/j.ejphar.2012.11.07123545365
   PubMed Web of Science ®Google Scholar
• AbeO, AbeR, EnomotoK, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467. doi:10.1016/S0140-6736(97)11423-49605801
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.. Lancet. 1992;339(8784):1–15.1345950
   PubMed Web of Science ®Google Scholar
• ColleoniM, GelberS, GoldhirschA, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol off J Am Soc Clin Oncol. 2006;24(9):1332–1341. doi:10.1200/JCO.2005.03.0783
   PubMed Web of Science ®Google Scholar
• KumarR, ZakharovMN, KhanSH, et al. The dynamic structure of the estrogen receptor. J Amino Acids. 2011;2011:1–7. doi:10.4061/2011/812540
   Google Scholar
• Kedia-MokashiN, MakawyAEL, SaxenaM, BalasinorNH. Chromosomal aberration in the post-implantation embryos sired by tamoxifen treated male rats. Mutat Res - Genet Toxicol Environ Mutagen. 2010;703(2):169–173. doi:10.1016/j.mrgentox.2010.08.016
   Web of Science ®Google Scholar
• BiancoS, GévryN. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription. 2012;3(4):165–170. doi:10.4161/trns.2049622771991
   PubMedGoogle Scholar
• NassN, KalinskiT. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract. 2015;211(3):189–197. doi:10.1016/j.prp.2015.01.00425666016
   PubMed Web of Science ®Google Scholar
• ZundelevichA, DadianiM, Kahana-EdwinS, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22(1):16. doi:10.1186/s13058-020-1246-532014063
   PubMed Web of Science ®Google Scholar
• LiS, ShenD, ShaoJ, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4(6):1116–1130. doi:10.1016/j.celrep.2013.08.02224055055
   PubMed Web of Science ®Google Scholar
• McGrawJ, WallerD. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8(3):371–382. doi:10.1517/17425255.2012.65762622288606
   PubMed Web of Science ®Google Scholar
• IgnatovA, IgnatovT, WeißenbornC, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat. 2011;128(2):457–466. doi:10.1007/s10549-011-1584-121607586
   PubMed Web of Science ®Google Scholar
• KangS, BaderA, VogtP. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102(3):802–807. doi:10.1073/pnas.040886410215647370
   PubMed Web of Science ®Google Scholar
• ZhaoW, ZhangQ, KangX, JinS, LouC. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. Biochem Biophys Res Commun. 2009;380(3):699–704. doi:10.1016/j.bbrc.2009.01.15519285025
   PubMed Web of Science ®Google Scholar
• RazaviP, ChangMT, XuG, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–438.e6. doi:10.1016/j.ccell.2018.08.00830205045
   PubMed Web of Science ®Google Scholar
• HuangD, YangF, WangY, GuanX. Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. Biochim Biophys Acta - Rev Cancer. 2017;1868(1):148–156. doi:10.1016/j.bbcan.2017.03.00828344099
   PubMed Web of Science ®Google Scholar
• LiJ, YenC, LiawD, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–1947. doi:10.1126/science.275.5308.19439072974
   PubMed Web of Science ®Google Scholar
• MillerTW, Pérez-TorresM, NarasannaA, et al. Loss of Phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009;69(10):4192–4201. doi:10.1158/0008-5472.CAN-09-004219435893
   PubMed Web of Science ®Google Scholar
• RahaP, ThomasS, MunsterPN. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011;3(4):451–470. doi:10.2217/epi.11.7222126205
   PubMed Web of Science ®Google Scholar
• Noriega-ReyesMY, Langley McCarronE. Estrogen receptor corregulators and their implication in breast cancer. Cancerology. 2008;3:29–40.
   Google Scholar
• HuangY, JiangD, SuiM, WangX, FanW. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. Oncol Rep. 2017;37:705–712. doi:10.3892/or.2016.531528000875
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. FDA approves first PI3K inhibitor for breast cancer. Press Announcements; 2019.
   Google Scholar
• ThorpeLM, YuzugulluH, ZhaoJJ. PI3K in cancer: divergent roles of isoforms, modes of activation, and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24. doi:10.1038/nrc386025533673
   PubMed Web of Science ®Google Scholar
• AndréF, CiruelosEM, RubovszkyG, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial. En: ESMO 2018 CONGRESS Vol 29; 2018 Available from:https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Alpelisib-ALP-fulvestrant-FUL-for-advanced-breast-cancer-ABC-results-of-the-Phase-3-SOLAR-1-trial. Accessed 113, 2020.
   Google Scholar
• BahramiN, ChangG, KanayaN, et al. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. J Steroid Biochem Mol Biol. 2020;200:105641. doi:10.1016/j.jsbmb.2020.10564132151708
   PubMed Web of Science ®Google Scholar
• GeislerJ, HelleH, EkseD, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14(19):6330–6335. doi:10.1158/1078-0432.CCR-07-522118829517
   PubMed Web of Science ®Google Scholar
• CarliniP, MichelottiA, FerrettiG, et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest. 2007;25(2):102–105. doi:10.1080/0735790070122478917453821
   PubMed Web of Science ®Google Scholar
• ChinYS, BeresfordMJ, RavichandranD, MakrisA. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast. 2007;16(4):436–439. doi:10.1016/j.breast.2007.02.00217418575
   PubMed Web of Science ®Google Scholar
• SharplessNE, SherrCJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15(7):397–408. doi:10.1038/nrc396026105537
   PubMed Web of Science ®Google Scholar
• SpringLM, WanderSA, ZangardiM, BardiaA. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25. doi:10.1007/s11912-019-0769-330806829
   PubMed Web of Science ®Google Scholar
• GoetzMP, ToiM, CamponeM, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi:10.1200/JCO.2017.75.615528968163
   PubMed Web of Science ®Google Scholar
• SledgeGW, ToiM, NevenP, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi:10.1200/JCO.2017.73.758528580882
   PubMed Web of Science ®Google Scholar
• DicklerMN, TolaneySM, RugoHS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–5224. doi:10.1158/1078-0432.CCR-17-075428533223
   PubMed Web of Science ®Google Scholar
• ChongQY, KokZH, BuiNLC, et al. A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib. Pharmacol Res. 2020;156:104686. doi:10.1016/j.phrs.2020.10468632068118
   PubMed Web of Science ®Google Scholar
• FinnRS, CrownJP, LangI, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised Phase 2 study. Lancet Oncol. 2015;16(1):25–35. doi:10.1016/S1470-2045(14)71159-325524798
   PubMed Web of Science ®Google Scholar
• HortobagyiGN, StemmerSM, BurrisHA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi:10.1056/NEJMoa160970927717303
   PubMed Web of Science ®Google Scholar
• TurnerNC, SlamonDJ, RoJ, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi:10.1056/NEJMoa181052730345905
   PubMed Web of Science ®Google Scholar
• KillockD. CDK4/6 inhibitors prolong OS. Nat Rev Clin Oncol. 2019;1.
   Google Scholar
• AsgharU, WitkiewiczAK, TurnerNC, KnudsenES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146. doi:10.1038/nrd450425633797
   PubMed Web of Science ®Google Scholar
• MillerTW, HennessyBT, González-AnguloAM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer. J Clin Invest. 2010;120(7):2406–2413. doi:10.1172/JCI4168020530877
   PubMed Web of Science ®Google Scholar
• VerretB, CortesJ, BachelotT, AndreF, ArnedosM. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019;30(Supplement_10):x12–x20. doi:10.1093/annonc/mdz381
   Web of Science ®Google Scholar
• MaCX, LuoJ, NaughtonM, et al. A Phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor–positive metastatic breast cancer. Clin Cancer Res. 2016;22(7):1583–1591. doi:10.1158/1078-0432.CCR-15-174526563128
   PubMed Web of Science ®Google Scholar
• KropIE, MayerIA, GanjuV, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(6):811–821. doi:10.1016/S1470-2045(16)00106-627155741
   PubMed Web of Science ®Google Scholar
• HurvitzSA, PeddiPF. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. Breast Dis. 2013;24(1):79–81. doi:10.1016/j.breastdis.2013.01.007
   Google Scholar
• DhakalA, Antony ThomasR, LevineEG, et al. Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast Cancer Basic Clin Res. 2020;14:1178223420944864. doi:10.1177/1178223420944864
   Web of Science ®Google Scholar
• LangedijkJ, Mantel-TeeuwisseAK, SlijkermanDS, SchutjensM-HDB. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027–1034. doi:10.1016/j.drudis.2015.05.00125975957
   PubMed Web of Science ®Google Scholar
• D’AmelioP, IsaiaGC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother. 2013;14(7):949–956. doi:10.1517/14656566.2013.78200223521229
   PubMed Web of Science ®Google Scholar
• WatersEA, McNeelTS, StevensWM, FreedmanAN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134(2):875–880. doi:10.1007/s10549-012-2089-222622807
   PubMed Web of Science ®Google Scholar
• LippmanME, CummingsSR, DischDP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res. 2006;12(17):5242–5247. doi:10.1158/1078-0432.CCR-06-068816951244
   PubMed Web of Science ®Google Scholar
• ShahRR, StonierPD. Repurposing old drugs in oncology: opportunities with clinical and regulatory challenges ahead. J Clin Pharm Ther. 2019;44(1):6–22.30218625
   PubMed Web of Science ®Google Scholar
• DenslowA, ŚwitalskaM, JaroszJ, et al. Clopidogrel in a combined therapy with anticancer drugs—effect on tumor growth, metastasis, and treatment toxicity: studies in animal models. PLoS One. 2017;12(12):e0188740. doi:10.1371/journal.pone.018874029206871
   PubMed Web of Science ®Google Scholar
• WhiteC, AlshakerH, CooperC, WinklerM, PchejetskiD. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016;7(17):23106. doi:10.18632/oncotarget.714527036015
   PubMed Web of Science ®Google Scholar
• PantziarkaP, BoucheG, MeheusL, SukhatmeV, SukhatmeVP, VikasP. The repurposing drugs in oncology (ReDO) project. Ecancermedicalscience. 2014;8. doi:10.3332/ecancer.2014.485
   Google Scholar
• BarokM, IsolaJ, Pályi-KrekkZ, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6(7):2065–2072. doi:10.1158/1535-7163.MCT-06-076617620435
   PubMed Web of Science ®Google Scholar
• ClynesRA, TowersTL, PrestaLG, RavetchJV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–446. doi:10.1038/7470410742152
   PubMed Web of Science ®Google Scholar
• PantziarkaP, BoucheG, MeheusL, SukhatmeV, SukhatmeVP. Repurposing drugs in oncology (ReDO) - mebendazole as an anti-cancer agent. Ecancermedicalscience. 2014;8(1). doi:10.3332/ecancer.2014.443
   Google Scholar
• NagataY, LanK, ZhouX, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–127. doi:10.1016/j.ccr.2004.06.02215324695
   PubMed Web of Science ®Google Scholar
• MoasserM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007;26(46):6577–6592. doi:10.1038/sj.onc.121047817486079
   PubMed Web of Science ®Google Scholar
• ShiY, FanX, MengW, DengH, ZhangN, AnZ. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation. Breast Cancer Res. 2014;16(2):R33. doi:10.1186/bcr363724693969
   PubMed Web of Science ®Google Scholar
• ScaltritiM, RojoF, OcañaA, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628–638. doi:10.1093/jnci/djk13417440164
   PubMed Web of Science ®Google Scholar
• NahtaR, YuD, HungMC, HortobagyiGN, EstevaFJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269–280. doi:10.1038/ncponc050916683005
   PubMedGoogle Scholar
• NagyP, FriedländerE, TannerM, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65(2):473–482.15695389
   PubMed Web of Science ®Google Scholar
• CampbellI, RussellS, ChoongD, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64(21):7678–7681. doi:10.1158/0008-5472.CAN-04-293315520168
   PubMed Web of Science ®Google Scholar
• WarmerdamP, Van de WinkelJ, VlugA, WesterdaalN, CapelP. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991;147(4):1338–1343.1831223
   PubMed Web of Science ®Google Scholar
• ChristiansonT, DohertyJ, LinY, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998;58(22):5123–5129.9823322
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves first PI3K inhibitor for breast cancer. FDA news release; 2019 Available from:https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer. Accessed 113, 2020.
   Google Scholar
• QuandtD, FiedlerE, BoettcherD, MarschWC, SeligerB. B7-h4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011;17(10):3100–3111.21378130
   PubMed Web of Science ®Google Scholar
• SwainSM, BaselgaJ, KimS-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa141351325693012
   PubMed Web of Science ®Google Scholar
• IshiiK, MoriiN, YamashiroH. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019;14:51–70. doi:10.2147/ce.s21784831802990
   PubMed Web of Science ®Google Scholar
• ZhangX, ChenJ, WengZ, et al. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. Mol Immunol. 2020;119:48–58. doi:10.1016/j.molimm.2020.01.00931978707
   PubMed Web of Science ®Google Scholar
• QinH, LiuL, SunS, et al. The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. PeerJ. 2018;6:e5092. doi:10.7717/peerj.509229942710
   PubMed Web of Science ®Google Scholar
• TranB, BedardPL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011;13(6):221. doi:10.1186/bcr290422217398
   PubMed Web of Science ®Google Scholar
• TongCWS, WuM, ChoW, ToKKW. Recent advances in the treatment of breast cancer. Front Oncol. 2018;8:227. doi:10.3389/fonc.2018.0022729963498
   PubMed Web of Science ®Google Scholar
• BarokM, JoensuuH, IsolaJ. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):1–12. doi:10.1186/bcr3621
   Web of Science ®Google Scholar
• ModiS, SauraC, YamashitaT, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa191451031825192
   PubMed Web of Science ®Google Scholar
• BegovacMQTc prolongation in patients treated with trastuzumab and ado-trastuzumab-emtazine; 2019 Available from:https://repozitorij.mef.unizg.hr/islandora/object/mef:2463. Accessed 113, 2020.
   Google Scholar
• HunterFW, BarkerHR, LipertB, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2019;122(5):603–612. doi:10.1158/1535-7163.MCT-17-029631839676
   PubMed Web of Science ®Google Scholar
• ModiS, TsurutaniJ, TamuraK, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: updated results of a large phase 1 study. Cancer Res. 2019;79(4Suppl):P6–17.
   Google Scholar
• SkidmoreL, SakamuriS, KnudsenN, et al. ARX788, a site-specific anti-HER2 antibody drug conjugate, demonstrates potent and selective activity in HER2 low and T-DM1 resistant breast and gastric cancers. Mol Cancer Ther. 2020:molcanther.1004.2019. doi:10.1158/1535-7163.MCT-19-1004.
   Web of Science ®Google Scholar
• NewmanDJ, CraggGM. Current status of marine-derived compounds as warheads in anti-tumor drug candidates. Mar Drugs. 2017;15(4):99. doi:10.3390/md15040099
   PubMed Web of Science ®Google Scholar
• BarokM, Le JoncourV, MartinsA, et al. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 2020;473:156–163. doi:10.1016/j.canlet.2019.12.03731904483
   PubMed Web of Science ®Google Scholar
• RinnerthalerG, GampenriederSP, GreilR. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 2019;20(5):1115. doi:10.3390/ijms20051115
   PubMed Web of Science ®Google Scholar
• YurkovetskiyA, GumerovD, Ter-OvanesyanE, et al. Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate. Cancer Res. 2017;77(13):48. doi:10.1158/1538-7445.AM2017-48
   Web of Science ®Google Scholar
• BergstromDA, BodyakN, ParkPU, et al. Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer. 2016. doi:10.1158/1538-7445.SABCS15-P4-14-28
   Google Scholar
• TraoreT, KhattarM. Abstract lb-294: synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (MAB) in a syngeneic breast cancer model expressing human HER2. 2018. doi:10.1158/1538-7445.AM2018-LB-294
   Google Scholar
• MurphyCG, ModiS. HER2 breast cancer therapies: a review. Biol Targets Ther. 2009;3:289–301. doi:10.2147/BTT.S3479
   PubMedGoogle Scholar
• RabindranSK, DiscafaniCM, RosfjordEC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958–3965. doi:10.1158/0008-5472.CAN-03-286815173008
   PubMed Web of Science ®Google Scholar
• LiM, HiranoK, IkedaY, et al. Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder. Orphanet J Rare Dis. 2019;14(1):1–9. doi:10.1186/s13023-019-1087-430606190
   PubMed Web of Science ®Google Scholar
• MoulderSL, BorgesVF, BaetzT, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin Cancer Res. 2017;23(14):3529–3536. doi:10.1158/1078-0432.CCR-16-149628053022
   PubMed Web of Science ®Google Scholar
• MurthyR, BorgesVF, ConlinA, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880–888. doi:10.1016/S1470-2045(18)30256-029804905
   PubMed Web of Science ®Google Scholar
• MurthyRK, LoiS, OkinesA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa191460931825569
   PubMed Web of Science ®Google Scholar
• BonnefoiH, GrelletyT, TredanO, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812–818. doi:10.1093/annonc/mdw06727052658
   PubMed Web of Science ®Google Scholar
• SubramanianS, PrasannaR, BiswasG, et al. Nanosomal docetaxel lipid suspension-based chemotherapy in breast cancer: results from a multicenter retrospective study. Breast Cancer Targets Ther. 2020;12:77–85. doi:10.2147/BCTT.S236108
   Web of Science ®Google Scholar
• LoiblS, FurlanettoJ. Targeting the immune system in breast cancer: hype or hope?: TILs and newer immune-based therapies being evaluated for HER2+ and TNBC. Curr Breast Cancer Rep. 2015;7(4):203–209. doi:10.1007/s12609-015-0193-0
   Google Scholar
• VerweijJ, ClavelM, ChevalierB. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann Oncol. 1994;5(6):495–505. doi:10.1093/oxfordjournals.annonc.a0589037918121
   PubMed Web of Science ®Google Scholar
• NorouziS, Gorgi ValokalaM, MosaffaF, ZirakMR, ZamaniP, BehravanJ. Crosstalk in cancer resistance and metastasis. Crit Rev Oncol Hematol. 2018;132:145–153. doi:10.1016/j.critrevonc.2018.09.01730447920
   PubMed Web of Science ®Google Scholar
• PonnusamyL, MahalingaiahPKS, ChangYW, SinghKP. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells. Eur J Pharm Sci. 2018;123:56–69. doi:10.1016/j.ejps.2018.07.02830016648
   PubMed Web of Science ®Google Scholar
• TangY, WangY, KianiMF, WangB. Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer. 2016;16(5):335–343. doi:10.1016/j.clbc.2016.05.01227268750
   PubMed Web of Science ®Google Scholar
• YuD, WuY, ShenH, et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 2015;106(8):959–964. doi:10.1111/cas.1271526052865
   PubMed Web of Science ®Google Scholar
• JiX, LuY, TianH, MengX, WeiM, ChoWC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800. doi:10.1016/j.biopha.2019.10880030921705
   PubMed Web of Science ®Google Scholar
• JingX, ZhangH, HuJ, et al. β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression. Int J Clin Exp Pathol. 2015;8(2):1354–1363.25973019
   PubMed Web of Science ®Google Scholar
• GaoX, WuY, QiaoL, FengX. SENP2 suppresses NF-κB activation and sensitizes breast cancer cells to doxorubicin. Eur J Pharmacol. 2019;854:179–186. doi:10.1016/j.ejphar.2019.03.05130940449
   PubMed Web of Science ®Google Scholar
• Dueñas-GonzalezA, CoronelJ, CetinaL, González-FierroA, Chavez-BlancoA, Taja-ChayebL. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014;10(10):1433–1444. doi:10.1517/17425255.2014.94726325154405
   PubMed Web of Science ®Google Scholar
• TanC, HuW, HeY, et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 2018;108:151–159. doi:10.1016/j.cyto.2018.03.02029609137
   PubMed Web of Science ®Google Scholar
• DeMicheleA, YeeD, EssermanL. Mechanisms of resistance to neoadjuvant chemotherapy in breast cancer. N Engl J Med. 2017;377(23):2287–2289. doi:10.1056/NEJMcibr171154529211674
   PubMed Web of Science ®Google Scholar
• TsuruoT, NaitoM, TomidaA, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003;94(1):15–21. doi:10.1111/j.1349-7006.2003.tb01345.x12708468
   PubMed Web of Science ®Google Scholar
• HasimMS, NessimC, VilleneuvePJ, VanderhydenBC, DimitroulakosJ. Activating transcription factor 3 as a novel regulator of chemotherapy response in breast cancer. Transl Oncol. 2018;11(4):988–998. doi:10.1016/j.tranon.2018.06.00129940414
   PubMed Web of Science ®Google Scholar
• DavisT, van NiekerkG, PeresJ, PrinceS, LoosB, EngelbrechtAM. Doxorubicin resistance in breast cancer: a novel role for the human protein AHNAK. Biochem Pharmacol. 2018;148:174–183. doi:10.1016/j.bcp.2018.01.01229309757
   PubMed Web of Science ®Google Scholar
• CrownJ. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol. 1999;26(1supl. 3):5–9.10203264
   PubMed Web of Science ®Google Scholar
• JaziehK, BellR, AgarwalN, AbrahamJ. Novel targeted therapies for metastatic breast cancer. Ann Transl Med. 2020;8(14):907. doi:10.21037/atm.2020.03.4332793751
   PubMed Web of Science ®Google Scholar
• GhaderiF, AhmadvandS, RamezaniA, MontazerM, GhaderiA. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. Biochem Biophys Res Commun. 2018;505(1):181–186. doi:10.1016/j.bbrc.2018.09.08730243716
   PubMed Web of Science ®Google Scholar
• MaruthanilaVL, ElancheranR, KunnumakkaraAB, KabilanS, KotokyJ. Recent development of targeted approaches for the treatment of breast cancer. Breast Cancer. 2017;24(2):191–219. doi:10.1007/s12282-016-0732-127796923
   PubMed Web of Science ®Google Scholar
• EstevaFJ, Hubbard-LuceyVM, TangJ, PusztaiL. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–e186. doi:10.1016/S1470-2045(19)30026-930842061
   PubMed Web of Science ®Google Scholar
• Le DuF, PerrinC, BrunotA, et al. Therapeutic innovations in breast cancer. Presse Med. 2019;48(10):1131–1137. doi:10.1016/j.lpm.2019.04.00531151842
   PubMed Web of Science ®Google Scholar
• MiklavčičD, MaliB, KosB, HellerR, SeršaG. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online. 2014;13(1):1–20. doi:10.1186/1475-925X-13-2924410918
   PubMed Web of Science ®Google Scholar
• MittalL, AryalUK, CamarilloIG, RamanV, SundararajanR. Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: a global proteomics study. Bioelectrochemistry. 2020;131:107350. doi:10.1016/j.bioelechem.2019.10735031518962
   PubMed Web of Science ®Google Scholar
• MittalL, RamanV, CamarilloIG, GarnerAL, SundararajanR. Viability and cell cycle studies of metastatic triple negative breast cancer cells using low voltage electrical pulses and herbal curcumin. Biomed Phys Eng Express. 2019;5(2):25040. doi:10.1088/2057-1976/aaf2c3
   Web of Science ®Google Scholar
• MittalL, CamarilloIG, VaradarajanGS, SrinivasanH, AryalUK, SundararajanR. High-throughput, label-free quantitative proteomic studies of the anticancer effects of electrical pulses with turmeric silver nanoparticles: an in vitro model study. Sci Rep. 2020;10(1):1–18. doi:10.1038/s41598-020-64128-831913322
   PubMed Web of Science ®Google Scholar
• AhmadA, SheikhS, TaranR, et al. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients. Clin Breast Cancer. 2014;14(3):177–181. doi:10.1016/j.clbc.2013.09.01124287370
   PubMed Web of Science ®Google Scholar
• MosesC, Garcia-BlojB, HarveyAR, BlancafortP. Hallmarks of cancer: the CRISPR generation. Eur J Cancer. 2018;93:10–18. doi:10.1016/j.ejca.2018.01.00229433054
   PubMed Web of Science ®Google Scholar
• WangH, SunW. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. Cancer Lett. 2017;385:137–143. doi:10.1016/j.canlet.2016.10.03327815036
   PubMed Web of Science ®Google Scholar
• LiuB, SaberA, HaismaHJ. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discov Today. 2019;24(4):955–970. doi:10.1016/j.drudis.2019.02.01130849442
   PubMed Web of Science ®Google Scholar
• YiL, LiJ. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Biochim Biophys Acta Rev Cancer. 2016;1866(2):197–207. doi:10.1016/j.bbcan.2016.09.002
   Web of Science ®Google Scholar
• MugheesM, KumarK, WajidS. Exosome vesicle as a nano-therapeutic carrier for breast cancer. J Drug Target. 2020;8:1–28. doi:10.1080/1061186X.2020.1808001
   Web of Science ®Google Scholar
• YongT, ZhangX, BieN, et al. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat Commun. 2019;10(1). doi:10.1038/s41467-019-11718-4
   Web of Science ®Google Scholar
• NassarFJ, NasrR, TalhoukR. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34–49. doi:10.1016/j.pharmthera.2016.11.01227916656
   PubMed Web of Science ®Google Scholar
• ÇalışkanM, GülerH, Bozok ÇetintaşV. Current updates on microRNAs as regulators of chemoresistance. Biomed Pharmacother. 2017;95:1000–1012. doi:10.1016/j.biopha.2017.08.08428922711
   PubMed Web of Science ®Google Scholar
• TomarD, YadavaAS, KumarD, BhadauriyaG, KunduGC. Non-coding RNAs as potential therapeutic targets in breast cancer. Biochim Biophys Acta Gene Regul Mech. 2019;863(4):194. doi:10.1016/j.bbagrm.2019.04.005
   Web of Science ®Google Scholar
• HoussenME, GhazyHF, FaragK, et al. Serum atrial natriuretic peptide: a suspected biomarker of breast cancer. Contemp Oncol. 2017;21(1):54. doi:10.5114/wo.2017.66657
   Google Scholar
• AleckK, HallmanK, QuigleyM, et al. Effects of atrial natriuretic peptide on p53 and estrogen receptor in breast cancer cells. BioResearch. 2017;6(1):141–150. doi:10.1089/biores.2017.0009
   Web of Science ®Google Scholar
• Van NuffelAMT, SukhatmeV, PantziarkaP, MeheusL, SukhatmeVP, BoucheG. Repurposing drugs in oncology (ReDO) - clarithromycin as an anti-cancer agent. Ecancermedicalscience. 2015;9:1–26. doi:10.3332/ecancer.2015.513
   Google Scholar
• GriffinF, MarignolL. Therapeutic potential of melatonin for breast cancer radiation therapy patients. Int J Radiat Biol. 2018;94(5):472–477. doi:10.1080/09553002.2018.144622729521142
   PubMed Web of Science ®Google Scholar
• AmaralMEA, NeryLR, LeiteCE, de AzevedoWF, CamposMM. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs. 2018;36(5):782–796. doi:10.1007/s10637-018-0568-y29392539
   PubMed Web of Science ®Google Scholar
• SharmaN, ThomasS, GoldenEB, et al. Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett. 2012;326(2):143–154. doi:10.1016/j.canlet.2012.07.02922863539
   PubMed Web of Science ®Google Scholar
• LambR, OzsvariB, LisantiCL, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget. 2015;6(7):4569. doi:10.18632/oncotarget.317425625193
   PubMed Web of Science ®Google Scholar
• IshidaJ, KonishiM, EbnerN, SpringerJ. Repurposing of approved cardiovascular drugs. J Transl Med. 2016;14(1):269. doi:10.1186/s12967-016-1031-527646033
   PubMed Web of Science ®Google Scholar
• GraçaI, SousaEJ, Costa-PinheiroP, et al. Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget. 2014;5(15):5950–5964. doi:10.18632/oncotarget.190924797896
   PubMedGoogle Scholar
• LiuB, HuangX, HuY, et al. Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer. Oncotarget. 2016;7(36):58038. doi:10.18632/oncotarget.1084627487128
   PubMedGoogle Scholar
• NiuG, LiaoZ, CaiL, WeiR, SunL. The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. Cancer Biother Radiopharm. 2008;23(4):469–476. doi:10.1089/cbr.2008.047518771351
   PubMed Web of Science ®Google Scholar
• HuJ, LjubimovaJY, InoueS, et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One. 2010;5(4):e10108. doi:10.1371/journal.pone.001010820419092
   PubMed Web of Science ®Google Scholar
• PantziarkaP, BryanBA, CrispinoS, DickersonEB. Propranolol and breast cancer—a work in progress. Ecancermedicalscience. 2018;12:1–6. doi:10.3332/ecancer.2018.ed82
   Google Scholar
• Chamaraux-TranTN, MathelinC, AprahamianM, et al. Antitumor effects of lidocaine on human breast cancer cells: an in vitro and in vivo experimental trial. Anticancer Res. 2018;38(1):95–105. doi:10.21873/anticanres.1219629277761
   PubMed Web of Science ®Google Scholar
• ParkS-H, ChungYM, MaJ, YangQ, BerekJS, HuMCT. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget. 2016;7(27):42110. doi:10.18632/oncotarget.988127283899
   PubMedGoogle Scholar
• ChenC-T, ChenY-C, YamaguchiH, HungM-C. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. Am J Cancer Res. 2015;5(12):3560.26885446
   PubMed Web of Science ®Google Scholar
• TuryS, AssayagF, BoninF, et al. The iron chelator deferasirox synergises with chemotherapy to treat triple‐negative breast cancers. J Pathol. 2018;246(1):103–114. doi:10.1002/path.510429876931
   PubMed Web of Science ®Google Scholar
• GohW, Sleptsova-FreidrichI, PetrovicN. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439–446. doi:10.18433/j3460825224353
   PubMed Web of Science ®Google Scholar
• GreenshieldsAL, FernandoW, HoskinDW. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp Mol Pathol. 2019;107:10–22. doi:10.1016/j.yexmp.2019.01.00630660598
   PubMed Web of Science ®Google Scholar
• TalaricoG, OrecchioniS, DallaglioK, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep. 2016;6:18673. doi:10.1038/srep1867326728433
   PubMed Web of Science ®Google Scholar
• ZhangL, WangX, ChenP. MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer. 2013;13:1–9. doi:10.1186/1471-2407-13-29023282137
   PubMed Web of Science ®Google Scholar
• ZengH, WangL, WangJ, et al. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2. Arch Biochem Biophys. 2018;651:52–60. doi:10.1016/j.abb.2018.05.01829802821
   PubMed Web of Science ®Google Scholar
• CochraneD, SpoelstraN, HoweE, NordeenS, RicherJ. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009;8(5):1055–1066. doi:10.1158/1535-7163.MCT-08-104619435871
   PubMed Web of Science ®Google Scholar
• BianX, LiangZ, FengA, SalgadoE, ShimH. HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL. Biochem Pharmacol. 2018;147:30–37. doi:10.1016/j.bcp.2017.11.00829155146
   PubMed Web of Science ®Google Scholar
• HanB, HuangJ, HanY, et al. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. Int J Biol Macromol. 2019;125:544–556. doi:10.1016/j.ijbiomac.2018.12.07530537505
   PubMed Web of Science ®Google Scholar
• GaoL, GuoQ, LiX, et al. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. EBioMedicine. 2019;41:395–407. doi:10.1016/j.ebiom.2019.02.03430803931
   PubMed Web of Science ®Google Scholar
• SetijonoSR, ParkM, KimO, KimY, Won ChoK, Jung SongS. miR-218 and miR-129 regulate breast cancer progression by targeting Lamins. Biochem Biophys Res Commun. 2018;496(3):826–833. doi:10.1016/j.bbrc.2018.01.14629378184
   PubMed Web of Science ®Google Scholar
• MuluhngwiP, KlingeCM. Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. Mol Cell Endocrinol. 2017;456:76–86. doi:10.1016/j.mce.2017.02.00428163101
   PubMed Web of Science ®Google Scholar
• Kagepura ThammaiahC, JayaramS. Role of let-7 family microRNA in breast cancer. Non-Coding RNA Res. 2016;1(1):77–82. doi:10.1016/j.ncrna.2016.10.003
   Google Scholar
• LiB, LuY, YuL, et al. miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation. Chem Biol Interact. 2017;277:33–42. doi:10.1016/j.cbi.2017.08.01428844858
   PubMed Web of Science ®Google Scholar
• EissaS, MatboliM, SharawyA, El-SharkawiF. Prognostic and biological significance of microRNA-221 in breast cancer. Gene. 2015;574(1):163–167. doi:10.1016/j.gene.2015.08.00426253160
   PubMed Web of Science ®Google Scholar
• GengW, SongH, ZhaoQ, et al. MiR-520h stimulates drug resistance to paclitaxel by targeting the OTUD3-PTEN axis in breast cancer. Biomed Res Int. 2020;2020:1–11. doi:10.1155/2020/9512793
   Web of Science ®Google Scholar